784,951 Shares of Immuneering Corporation $IMRX Acquired by Aberdeen Group plc

Aberdeen Group plc bought a new position in shares of Immuneering Corporation (NASDAQ:IMRX – Free Report) in the third quarter, Holdings Channel.com reports. The firm bought 784,951 shares of the company’s stock, valued at approximately $3,214,000.

Several other large investors have also recently modified their holdings of the business. Integrated Wealth Concepts LLC purchased a new position in Immuneering during the 2nd quarter valued at about $34,000. Levin Capital Strategies L.P. bought a new stake in shares of Immuneering during the first quarter valued at about $53,000. VestGen Advisors LLC lifted its holdings in shares of Immuneering by 100.0% in the third quarter. VestGen Advisors LLC now owns 20,002 shares of the company’s stock worth $82,000 after buying an additional 10,002 shares in the last quarter. Principle Wealth Partners LLC purchased a new stake in shares of Immuneering in the third quarter worth about $51,000. Finally, Focus Financial Network Inc. bought a new position in shares of Immuneering in the second quarter valued at approximately $62,000. Hedge funds and other institutional investors own 67.65% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on IMRX. HC Wainwright reiterated a “buy” rating on shares of Immuneering in a research report on Friday, October 30th. Wall Street Zen upgraded Immuneering from a “strong sell” rating to a “sell” rating in a research report on Saturday. Chardan Capital upgraded Immuneering to a “strong-buy” rating in a research note on Monday, August 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Immuneering in a research note on Monday, September 21st. Finally, UBS Group set a $14.00 price target on Immuneering in a report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $15.67.

View Our Latest Report on Immuneering

Immuneering Stock Down 2.0%

NASDAQ:IMRX opened at $3.38 on Friday. The stock has a market cap of $218.89 million, a PE ratio of -3.28 and a beta of 0.49. The business’s 50-day simple moving average is $3.88 and its two-hundred day simple moving average is $4.70. Immuneering Corporation has a 52 week low of $3.29 and a 52 week high of $8.48.

Immuneering (NASDAQ:IMRX – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.06). Sell-side analysts anticipate that Immuneering Corporation will post -1.22 earnings per share for the current fiscal year.

Immuneering Company Profile

(Free Report)

Immuneering Corporation is a clinical-stage biotechnology company developing medicines for cancer. The company uses computational biology and drug-discovery approaches to study disease patterns and identify potential therapeutic targets, with a focus on the MAPK signaling pathway, which is involved in many cancers. Its lead drug candidate, atebimetinib (IMM-1-104), is an oral investigational therapy designed to inhibit MEK proteins and disrupt MAPK signaling. Immuneering is evaluating this candidate for solid tumors, including pancreatic cancer, and is advancing additional drug candidates aimed at cancer-related pathways.

See Also

Want to see what other hedge funds are holding IMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immuneering Corporation (NASDAQ:IMRX – Free Report).

Institutional Ownership by Quarter for Immuneering (NASDAQ:IMRX)

Receive News & Ratings for Immuneering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuneering and related companies with MarketBeat.com's FREE daily email newsletter.